Brief: Affluent Medical FY Net Loss Widens To EUR 14.8 Million

Carvolix SA

29/03/2022 17:15

March 29 (Reuters) - Affluent Medical SAS  AFME.PA :
    * 2021 FULL-YEAR RESULTS AND UPDATE ON CLINICAL PROGRAMS
    * CASH AT THE END OF DECEMBER 2021 STOOD AT €11,410K,
COVERING
FINANCING NEEDS UP TO SEPTEMBER 2022.
    * FY NET LOSS EUR 14.8 MILLION VERSUS LOSS EUR 14.3 MILLION
YEAR
AGO
    * FY CURRENT OPERATING INCOME LOSS OF EUR 13.233 MILLION
VERSUS
LOSS OF EUR 12.594 MILLION YEAR AGO
    * FOR ARTUS: WILL SUBMIT APPLICATION FOR BREAKTHROUGH
THERAPY
DESIGNATION 5  4  WITH FDA IN ANTICIPATION OF LAUNCH OF A
PIVOTAL STUDY IN UNITED STATES WHICH COULD BEGIN IN 2023 FOR
MARKETING IN 2025
    * UPDATE ON CLINICAL PROGRAMS: AFFLUENT MEDICAL'S OBJECTIVE
IS TO
BE ABLE TO MARKET KALIOS IN EUROPE FROM 2024
    * UPDATE ON CLINICAL PROGRAMS: EPYGON: LAUNCH OF "FIRST-IN
HUMAN"
CLINICAL STUDY IN 2022 FOR MARKETING IN EUROPE IN 2026
    * IN 2021, THE OPERATING RESULT IS -13,247 K 

Source text for Eikon:  ID:nEQc8z0zta 
Further company coverage:  AFME.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))